|
Advancing Lymphatic Endothelial Cell Generation from iPSCs
Application
The developed protocol offers a reproducible and scalable method for generating lymphatic endothelial cells (LECs) from induced pluripotent stem cells (iPSCs), addressing critical challenges in the field of lymphatic-related therapies.
Key Benefits
Reproducible and scalable protocol for generating LECs from iPSCs.
Utilizes specific...
Published: 2/13/2025
Updated: 8/5/2024
Inventor(s): Katherine Hekman, Katherine Owsiany
|
|
Guiding the Cartilage Repair Microenvironment
Application
A novel method to improve the effectiveness of marrow-mediated cartilage repair.
Key Benefits
Enhances the efficacy of the marrow stimulation procedure for cartilage repair.
Priming the cartilage repair environment to enable subsequent healthy tissue growth.
Potential to become a one-step, implementable, and effective treatment for...
Published: 2/13/2025
Updated: 8/5/2024
Inventor(s): Sameh Labib, David Myers, Jay M. Patel, Maddie Hasson, Lorenzo Fernandes
|
|
Optimizing the Engineering of CAR-T Cells
Application
A method for selecting distinct T cell populations in order to generate more effective CAR-T cells.
Key Benefits
The proposed invention focuses on selecting the optimal “starting material” for the engineering CAR-T cells.
This selection method can be utilized for the development of any and all CAR-T therapies, not limited...
Published: 2/13/2025
Updated: 8/5/2024
Inventor(s): Byron Au-Yeung
|
|
Improving CAR T cell efficacy with Cytokine-Loaded Microparticles
Application
Novel reagents for manufacturing of CAR T cells with improved characteristics.
Key Benefits
A multi-cytokine backpack particle that can be used during manufacturing process of CAR T treatments to improve their phenotype and efficacy.
Preliminary data show the method can transduce primary healthy and patient T cells and promote CAR...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Sarwish Rafiq, Erik Dreaden, A K M Nawshad Hossian, Biaggio Uricoli
|
|
Isolation of Therapeutic cells and Framework for Adoptive Cell Therapies
Application
Isolation of therapeutic cells and framework for adoptive cell therapies based around stem-like chronic memory CD8 T cells that may be paired with PD-1 blockade.
Key Benefits
Persistent cell survival and therapeutic efficacy following rechallenge with chronic viral infection and cancer.
Strong co-treatment potential with PD-1...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Rafi Ahmed, Daniel Chang
|
|
PNP-based Solid Tumor Therapy in Conjunction with Checkpoint Blockade Inhibitors
Application
Treatment of solid tumors combining purine nucleoside phosphorylase (PNP) technology with checkpoint blockade inhibition.
Key Benefits
Safe and effective method for markedly enhancing checkpoint blockade therapy for refractory tumors.
Checkpoint inhibitor therapy is FDA-approved and already in use.
Market Summary
Checkpoint blockade...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Eric J. Sorscher, Turang Behbahani, Regina Rab, Annette Ehrhardt, Jeong Hong, Disha Joshi
|
|
Platform for Transducing Target Cells with a Viral Vector
Application
System for quickly and efficiently obtaining therapeutic levels of transduction.
Key Benefits
Uses less viral vector to achieve high gene transfer.
Shortens transduction time.
Produces clinically relevant gene modified cell numbers.
Market Summary
Information relay at the molecular level, such as the transcription of RNA into proteins,...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Reginald Tran, Wilbur Lam, Christopher Doering, H. (Harold) Trent Spencer
|
|
High-Throughput Platform for Imaging and Maintaining Cells in Culture
Application
This closed-loop platform monitors and maintains traditional cell culture and bioengineered tissues to automate standard and custom cell maintenance protocols, including stem cell differentiations, bioengineered tissue generation, and functional maturation of complex cell cultures.
Key Benefits
Automation of cell culture maintenance
Integration...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Vahid Serpooshan, Ayda Melika, Amir Pourmorteza
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|
|
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application
Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages.
Key Benefits
Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi.
Relatively low regulatory risk because many...
Published: 2/13/2025
Updated: 4/7/2023
Inventor(s): Young-Sup Yoon, Ji Woong (Jay) Han, Hyunsuk Shim
|
